Monday, August 10, 2026’s bullish board is a study in contrasts. A biotech is up 35% for the second straight session on data its CEO called blockbuster-caliber. A defense contractor just closed out a seven-day, 38% winning streak. Berkshire Hathaway punched through a new 52-week high on its way back toward a trillion-dollar valuation. And sitting right in the middle of this bullish list is an ad-tech name in genuine freefall — a reminder that “trending” and “bullish” aren’t always the same thing on any given session. Here is the full breakdown of today’s 10 most bullish stocks and symbols, with every number, every catalyst, and the support and resistance levels traders are watching next.

Most Bullish Stocks Today — Aug 10, 2026:

1. TTD — The Trade Desk Inc | $13.11 | −5.00% | Volume: 41.92M | Market Cap: $6.49B

Full Data Snapshot:

The Honest Assessment First: TTD does not belong on a “bullish” list by any traditional definition today — it’s included here because it is, by a wide margin, the most consequential mover on the board, and because its collapse is directly reshaping sentiment across the entire ad-tech sector. Readers should treat this entry as a bearish outlier flagged for its market-moving importance, not a buy signal.

What’s Driving the Collapse:

• The Trade Desk reported Q2 2026 revenue of $715.06 million, missing the $751.35–$752.1 million consensus, with adjusted EPS of $0.34 against a $0.40 estimate.
• Third-quarter guidance called for revenue of no less than $650 million — a 12% year-over-year decline and roughly 19.4% below what analysts had previously modeled. Adjusted EBITDA margin guidance fell to 24.6% from 43% a year earlier.
• The stock has now fallen as much as 27.3% intraday since the report, touching its lowest level since early 2019, and is down 24.6% over the past week alone.

The Analyst Rout: HSBC downgraded to Reduce and cut its target in half to $10. Citi moved to Sell with an $11 target. Morgan Stanley cut its target to $13 from $26 while holding Equal Weight. Raymond James downgraded to Underperform. The number of Hold ratings has climbed to 29, with Buy ratings falling to just six. Notably, peers like AppLovin (down 2%) and Magnite (down 2%) are only modestly softer today, confirming this is a Trade Desk execution problem rather than a sector-wide rout — CEO Jeff Green has responded with a leadership reset, naming a new CFO, CMO, Chief Commercial Officer, and Chief Business Development Officer.

Technical Levels:

2. KTOS — Kratos Defense & Security Solutions | $62.31 | +2.53% | Volume: 3.54M | Market Cap: $11.41B

Full Data Snapshot:

A Genuine, Structural Bullish Story:

Kratos is riding one of the cleanest beat-and-raise setups on today’s board, now on a seven-consecutive-day winning streak that has added roughly $3.2 billion to its market value.

The beat was driven by strength across hypersonics, engines, and space programs, and Kratos also landed a new U.S. Army contract in the days following the print. Analyst reaction has been broadly positive: Canaccord raised its target to $135 from $130, BTIG lifted its target to $104 from $100, and Piper Sandler upgraded the stock to Overweight from Neutral. Not every voice is fully on board — Stifel trimmed its target to $115 from $134 even while keeping a Buy rating, flagging valuation after the run, with the stock now trading at a steep 370.9x price-to-earnings multiple against a 1.5% operating margin.

Technical Levels:

3. ABCL — AbCellera Biologics | $9.39 | +35.50% | Volume: 42.83M | Breaking 52-Week High Again

Full Data Snapshot:

Still Riding Friday’s Blockbuster Data:

AbCellera’s surge is a continuation of the move that began when the company reported positive topline Phase 2 results for ABCL635, its non-hormonal treatment for moderate-to-severe hot flashes tied to menopause. The randomized, placebo-controlled trial in 92 postmenopausal women showed an 83% mean reduction in hot flash frequency at week four, with a placebo-adjusted difference of 8.8 events per day versus 3.5 for placebo. CEO Carl Hansen told investors the data was “beyond even the most aggressive upside scenario we had dared to consider.”

The mechanism matters as much as the number: ABCL635 is a potential first-in-class antibody targeting NK3R, the neurokinin 3 receptor involved in body temperature regulation, positioning it as a non-hormonal option for roughly 30 million U.S. women for whom standard hormone therapy is contraindicated. Safety was clean, with no serious adverse events and no discontinuations. A separate Vertex collaboration bringing $28 million upfront, with Vertex funding R&D through Phase 1, adds a second, independent bullish catalyst. Stifel and Cantor Fitzgerald have raised targets to $9 and $12, respectively.

Technical Levels:

4. BRK.B — Berkshire Hathaway Class B | $527.22 | +1.04% | New 52-Week High | Market Cap: $1.01T

Full Data Snapshot:

A Textbook Defensive Rotation Signal:

Berkshire trading above its own 52-week high while sitting on more than $330 billion in cash is one of the clearest expressions of defensive positioning available in the market today. With the Dow having fallen roughly 1,100 points on July 29 and the AI-networking and ad-tech trades both wobbling badly this week, capital continues rotating toward Berkshire’s diversified, reliably-earning businesses. The $1.01 trillion market cap keeps Berkshire in the same rarefied company as Apple, Nvidia, Microsoft, Amazon, and Alphabet — an unusual feat for a company with no dividend and no formal near-term buyback commitment at current prices.

Technical Levels:

5. SENS — Senseonics Holdings | $7.49 | +6.70% | Volume: 1.4M | Market Cap: $366.46M

Full Data Snapshot:

A Small-Cap CGM Story Building Momentum:

Senseonics is extending gains following an August 6 earnings report that beat consensus on EPS (a loss of $0.63 versus an expected loss of $0.62) alongside a genuinely strong operational update: Q2 revenue grew 120% year over year, and the company raised full-year revenue guidance to a range of $62 million to $66 million. Lake Street reiterated a Buy rating with an unchanged $14 price target following the print, calling out accelerating growth and pipeline progress. The company’s Eversense 365 implantable continuous glucose monitor continues gaining U.S. commercial traction, and its Eon Care telehealth network has now crossed 90 participating providers.

The Balance Sheet Caveat: Senseonics carried out an $80 million public stock offering earlier this year at $5.00 per share — a dilutive event investors should weigh against the operational momentum, since further capital raises remain a real possibility given the company’s continued net losses (a $36.7 million net loss last quarter).

Technical Levels:

6. APPS — Digital Turbine Inc | $14.39 | +0.35% | Volume: 2.28M | Market Cap: $1.74B

Full Data Snapshot:

Consolidating Near the Top After an Explosive Run:

Digital Turbine’s modest gain today belies an extraordinary multi-week move — the stock is up more than 400% from its 52-week low, fueled by a blowout fiscal Q1 report (revenue of $166 million, up 27% year over year, versus a $150 million consensus, with EPS of $0.19 topping the $0.14 estimate) and raised full-year guidance to $650–$670 million. Today’s near-flat action, sitting just below its 52-week high of $15.34, looks like healthy consolidation rather than exhaustion — a pause that lets the stock’s rally digest before its next potential leg, provided no negative catalyst intervenes.

Technical Levels:

7. TMDX — TransMedics Group | $87.58 | +4.40% | Volume: 974,378 | Market Cap: $2.91B

Full Data Snapshot:

Recovering From a Mixed Earnings Reaction:

TransMedics is bouncing today after a choppy stretch following its August 4 Q2 report. The headline numbers were mixed: total revenue of $189.9 million (up 21% year over year) and net income of $14.7 million topped prior guidance, but adjusted EPS of $0.44 missed the $0.48–$0.52 consensus. Management raised the low end of full-year 2026 revenue guidance (excluding the newly acquired PAD Aviation business) to $737–$757 million from $727–$757 million. The organ-transplant technology company’s average analyst rating remains a “Buy,” with a 12-month price target of $116.78 implying meaningful upside from current levels, even as Stifel and Oppenheimer have both taken more cautious stances following the print, citing regulatory headwinds and donor-supply volatility.

Technical Levels:

8. PGEN — Precigen Inc | $7.05 | −2.49% | Volume: 3.15M | Market Cap: $2.59B

Full Data Snapshot:

A Genuine Beat, Now Facing a Governance Question:

Precigen delivered one of the cleanest commercial-stage biotech beats of the quarter — Q2 revenue of $55.0 million against a $27.83 million consensus, powered by PAPZIMEOS net revenue surging over 145% sequentially to $53.1 million at a 95% gross margin. H.C. Wainwright responded by raising its price target to $18 from $14 while maintaining a Buy rating. Today’s modest pullback comes as the stock sits just below its freshly set 52-week high of $7.26, and follows reports that stirred investor concern over changes to the CEO’s trading plan — a governance headline that’s introduced some caution even against an otherwise strong fundamental backdrop. PAPZIMEOS also recently received orphan drug exclusivity in the U.S., extending market protection through August 2032.

Technical Levels:

9. HNST — The Honest Company | $5.25 | −3.94% | Volume: 3.28M | Market Cap: $585.77M

Full Data Snapshot:

Giving Back a Slice of Last Week’s Explosive Rally:

Honest Company’s pullback today follows an enormous 41% single-day surge on August 6, triggered by a Q2 beat (EPS of $0.09 versus a $0.01 consensus) and raised full-year revenue guidance to $319–$325 million from a prior $306–$312 million. That print set off a wave of price target increases: Freedom Broker upgraded the stock to Buy with a target raise, while B. Riley, Telsey Advisory, and Alliance Global all lifted their targets to the $5.00–$5.50 range. Management’s plan to reinvest tariff refunds into higher-margin product categories, alongside the ongoing “Powering Honest Growth” strategy, has also lifted fair-value estimates from roughly $4.07 to $4.82 in recent models. Today’s dip looks like routine profit-taking after an outsized move rather than a reversal of the underlying thesis.

Technical Levels:

10. WDC — Western Digital Corp | $439.19 | +1.13% | Volume: 5.22M | Market Cap: $149.7B

Full Data Snapshot:

Stabilizing After a Volatile Post-Earnings Week:

Western Digital is edging higher today after a bruising stretch that saw the stock slide alongside SanDisk despite both companies beating Q4 estimates on their respective August 5-6 reports — a “sell the beat” reaction driven by the market’s demand for even more aggressive forward guidance in the white-hot NAND and enterprise SSD trade. WDC’s 500%-plus gain from its 52-week low reflects the broader AI-data-center storage boom that has repriced the entire memory sector this year, even as the stock remains 45% below its own 52-week high, underscoring just how volatile this trade has become in both directions.

Technical Levels:

August 10 Most Bullish Stocks — Full Summary

Follow TNN for daily stock market news and financial news today.

Disclaimer: This publication is entirely for informational and journalistic purposes and does not constitute formal financial, investment, or legal advice. All market investments carry inherent risks of capital loss. Support and resistance levels cited are technical analysis estimates based on historical price data and do not guarantee future price behaviour. Always complete independent due diligence prior to executing equity trades.

About The Author

Nichole Miller

See author's posts